November 28, 2019

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

TORONTO, CANADA — (November 28, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019. … Continued

read

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

TORONTO, CANADA — (August 27, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The Company’s unaudited fiscal Q1 2020 condensed interim consolidated financial statements and MD&A are available on SEDAR. In addition, … Continued

read
August 13, 2019

Antibe Announces Closing of Public Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (August 13, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced public offering of 26,833,332 … Continued

read
August 7, 2019

Antibe Therapeutics Announces Filing of Final Short Form Prospectus

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (August 7, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, announces that it has filed a final short form prospectus (the “Final Prospectus”) relating to … Continued

read
July 25, 2019

Antibe Therapeutics Announces Size of Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (July 25, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, announces that its previously-announced marketed offering (the “Offering”) of units of the Company … Continued

read
July 23, 2019

Antibe Therapeutics Announces Offering of Units

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (July 23, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has filed a preliminary short form prospectus (the “Preliminary … Continued

read
July 16, 2019

Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

TORONTO, CANADA — (July 16, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company’s audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR. About Antibe … Continued

read
July 2, 2019

Antibe Therapeutics Announces Results of Annual General and Special Meeting

TORONTO, CANADA — (July 2, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel … Continued

read
June 25, 2019

Antibe Therapeutics Announces CEO Letter to Shareholders

TORONTO, ONTARIO – (June 25, 2019) To our shareholders, As we approach the end of Phase 2 development for ATB-346 and launch into global partnering discussions, we thought this would be an ideal time to reflect on recent developments and reiterate our strategy to maximize value for shareholders. Last year was pivotal for Antibe as … Continued

read
June 3, 2019

Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain

TORONTO, CANADA — (June 3, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain. The Company will be … Continued

read
May 30, 2019

Antibe Therapeutics Announces Upcoming Conference Schedule

TORONTO, CANADA — (May 30, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference schedule for the upcoming months. 2019 BIO International Convention (June 3 – 6, 2019) – Philadelphia, United States Antibe will be engaging … Continued

read
April 16, 2019

Phase 2B GI Safety Results for ATB-346 Published in British Journal of Pharmacology

TORONTO, CANADA — (April 16, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today highlights that a research article has been published in the British Journal of Pharmacology (“BJP”) on the successful Phase 2B GI safety trial for its lead drug, … Continued

read
March 29, 2019

Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346

TORONTO, CANADA — (March 29, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that its Phase 2B dose-ranging, efficacy study for ATB-346 has formally commenced. Enrolment is open, clinical sites have been activated and patients will now … Continued

read
February 27, 2019

Antibe Therapeutics Announces Closing of $5.75 Million Bought Deal Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Underwriters Exercise Over-Allotment Option in Full TORONTO, CANADA — (February 27, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has closed … Continued

read
February 22, 2019

Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company

TORONTO, CANADA — (February 22, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been named a 2019 TSX Venture 50™ company, an award that recognizes the top performing companies on the TSX Venture Exchange … Continued

read
February 15, 2019

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

TORONTO, CANADA — (February 15, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antibe Therapeutics … Continued

read
February 4, 2019

Antibe Therapeutics Announces $5 Million Bought Deal Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (February 4, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an agreement with Bloom Burton Securities … Continued

read
January 21, 2019

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO, CANADA — (January 21, 2019) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The primary … Continued

read

archives